Skip to content
  • Home
  • Company
    • About Us
    • Leadership
    • Management
    • Board of Directors
    • Scientific
      Advisory Board
  • Science
    • Evorpacept
    • Publications
  • Pipeline
    • Clinical Trials
    • Expanded
      Access Policy
  • Careers
    • Current Jobs
  • Investors
    • Overview
    • News & Events
    • Stock Information
    • Corporate Governance
    • Financials & Filings
    • IR Resources
  • Contact

Targeting the Myeloid Checkpoint Receptor SIRPα Potentiates Innate and Adaptive Immune Responses to Promote Anti‑Tumor Activity

Post navigation

Previous: ALX148, a CD47 Blocker, in Combination with Standard Chemotherapy and Antibody Regimens in Patients with Gastric/Gastroesophageal Junction (GC) Cancer and Head and Neck Squamous Cell Carcinoma (HNSCC); ASPEN-01
Next: ALX148 Enhances the Depth and Durability of Response to Multiple AML Therapies
TOP
  • Home
  • Company
    • About Us
    • Leadership
    • Management
    • Board of Directors
    • Scientific
      Advisory Board
  • Science
    • Evorpacept
    • Publications
  • Pipeline
    • Clinical Trials
    • Expanded
      Access Policy
  • Careers
    • Current Jobs
  • Investors
    • Overview
    • News & Events
    • Stock Information
    • Corporate Governance
    • Financials & Filings
    • IR Resources
  • Contact
© ALX Oncology Inc., All rights reserved.
Privacy Policy Twitter LinkedIn